In vitro activity of iclaprim against respiratory and bacteremic isolates of streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1690-1692

  Zhanel, George ^a   Karlowsky, James A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ICLAPRIM; PENICILLIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; DILUTION; DRUG ACTIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

BACTEREMIA; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; RESPIRATORY SYSTEM; STREPTOCOCCUS PNEUMONIAE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 65649117761     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01388-08     Document Type: Article

References (15)

1. 1. Andrews, J., D. Honeybourne, J. Ashby, G. Jevons, A. Fraise, P. Fry, S. Warrington, S. Hawser, and R. Wise. 2007. Concentrations in plasma, epi-thelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J. Antimicrob. Chemother. 60:677-680. (Pubitemid 47299890)
2. Appelbaum, P. C, and M. R. Jacobs. 2005. Recently approved and investi-gational antibiotics for treatment of severe infections caused by gram-posi-tive bacteria. Curr. Opin. Microbiol. 8:510-517. (Pubitemid 41355030)
3. Bozdogan, B., D. Esel, C. Whitener, F. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey medical center. J. Antimicrob. Chemother. 52:864-868. (Pubitemid 37407819)
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement, vol.27, no. 1. M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Hawser, S., S. Lociuro, and K. Islam. 2006. Dihydrofolate reductase inhib-itors as antibacterial agents. Biochem. Pharmacol. 71:941-948. (Pubitemid 43306786)
7. Kohlhoff, S. A., P. M. Roblin, T. Reznik, S. Hawser, K. Islam, and M. R. Hammerschlag. 2004. In vitro activity of a novel diaminopyrimidine com-pound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimi-crob. Agents Chemother. 48:1885-1886. (Pubitemid 38544405)
8. Lynch, J. P., and G. G. Zhanel. 2005. Antimicrobial resistant Streptococcus pneumoniae: implications for therapy. Semin. Respir. Crit. Care Med. 26: 575-616. (Pubitemid 41264118)
9. Sahm, D. F., N. P. Brown, D. C. Draghi, A. T. Evangelista, Y. C. Yee, and C. Thornsberry. 2008. Tracking resistance among bacteriai respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad. Med. 120(Suppl. 1):8-15.
10. Schneider, P., S. Hawser, and K. Islam. 2003. Iclaprim, a novel diaminopy-rimidine with potent activity on trimethoprim sensitive and resistant bacte-ria. Bioorg. Med. Chem. Lett. 13:4217-4221. (Pubitemid 37410316)
11. Sorberá, L. A., J. Castaner, and X. Rabasseda. 2004. Iclaprim (AR-100, Ro-48-2622). Drugs Future 29:220-225.
12. Tenover, F. C, L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chait-ram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48:275-280. (Pubitemid 38040208)
13. Trampuz, A., and A. F. Widmer. 2006. Infections associated with orthopedic implants. Curr. Opin. Infect. Dis. 19:349-356. (Pubitemid 43982507)
14. Zhanel, G. G., L. Palatnick, K. A. Nichol, T. Bellyou, D. E. Low, and D. J. Hoban. 2003. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Suscep-tibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47:1867-1874. (Pubitemid 36637807)
15. Zhanel, G. G., X. Wang, K. Nichol, A. Nikulin, A. Wierzbowski, M. Mulvey, and D. J. Hoban. 2006. Canadian pediatric multi-drug resistant Streptococcus pneumoniae from 1998-2004: epidemiology evolution and characterization. Int. J. Antimicrob. Agents 28:465-471. (Pubitemid 44636174)